Will Rise in Coagulation Disorders Fuel Demand for Point-of-Care Testing Systems: Fact.MR

Fact.MR – market research and competitive intelligence provider, projects the global hemostasis diagnostics market to accelerate at a CAGR of above 7% across the 2021-2031 forecast period.

Hemostasis diagnostics are devices that help in the identification of hemostatic defects, which leads to excessive bleeding. Hemostasis is a process of slowing and stopping blood flow to initiate wound healing after a vascular injury, and is a key procedure acting at the first line of action adopted by the body.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=6742

During the process, blood changes its form from the fluid state to the gelatinous state. Hemostasis is maintained in the body via three mechanisms, namely, vasoconstriction, platelet plug formation, and blood coagulation. Diagnosis helps predict the cause of excessive bleeding during a surgery, and identifies hemostatic defects in patients with a history of excessive bleeding.

Increased occurrence of genetically inherited diseases is likely to fuel demand for hemostasis diagnostics. Increased prevalence of hemostasis disorders is also set to drive market expansion over the coming years.

Key Takeaways from Market Study

• Global hemostasis diagnostics market to top US$ 7.5 Bn by 2031.
• Laboratory systems projected to reach around US$ 940 Mn by 2031.
• Consumables projected to record around 5% CAGR over next 10 years.
• Market in Japan to record 3% CAGR over forecast period of 2021- 2031.
• China forecast to reach projected market size above US$ 800 Mn.
• Market in Canada projected to expand above 6% CAGR over next 10 years.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=6742

Market Categorization as Per Hemostasis Diagnostics Industry Research

Product

• Laboratory Systems
• Consumables
• Point-of-Care Testing Systems

Test

• Prothrombin Test Time (PT)
• Activated Partial Thromboplastin Time (APTT)
• Fibrinogen Degradation Products (FDP)
• Activated Clotting Time
• Platelet Aggregation Test
• D Dimer

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/6742

Market Competition

Key manufacturers of hemostasis diagnostic products are engaged in regulatory approvals, manufacturing technologically advanced products, launching of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel overall growth of the market.

A few expansion strategies adopted by players are:

• In 2016, Siemens Healthineers launched Sysmex CS-2500, a new mid-volume coagulation analyzer, which enable labs to provide quality test results and achieve cost-effective method consolidation.
• In April 2017, Starch Medical Inc. expanded its hemostasis portfolio with the launch of SuperClot Hemostat in Europe.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com